{"name":"Chengdu New Radiomedicine Technology Co. LTD.","slug":"chengdu-new-radiomedicine-technology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"NRT6003 Injection","genericName":"NRT6003 Injection","slug":"nrt6003-injection","indication":"Cancer (specific indication not publicly disclosed)","status":"phase_3"},{"name":"cTACE","genericName":"cTACE","slug":"ctace","indication":"Hepatocellular carcinoma","status":"phase_3"}]}],"pipeline":[{"name":"NRT6003 Injection","genericName":"NRT6003 Injection","slug":"nrt6003-injection","phase":"phase_3","mechanism":"NRT6003 is a radiopharmaceutical injection designed to deliver targeted radiation therapy to cancer cells.","indications":["Cancer (specific indication not publicly disclosed)"],"catalyst":""},{"name":"cTACE","genericName":"cTACE","slug":"ctace","phase":"phase_3","mechanism":"cTACE involves the direct injection of chemotherapy drugs into liver tumors via the hepatic artery.","indications":["Hepatocellular carcinoma","Metastatic liver cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQNGQ4N1JlR185NDQ0YjFZRVNLb2dWSGp0ajlPSmJURlZ2Y3lSSXNMV3BIZkw0Qm1VcS13aEJkUUhvN24xSzA2eXI5Z05URlQwSUsxTzJXY0RodDRRcktvRUNSZFN4eTZZbE1xSUcybHVuclpXOEhCZTNYUHN4TjFka2g0dW85RjgtVW5RN2E4UGpnUjVrSHB4VDhn?oc=5","date":"2026-04-08","type":"pipeline","source":"The Pharma Letter","summary":"NRT lands $145 million to push radiopharma pipeline | Pharmaceutical | The Pharmaletter - The Pharma Letter","headline":"NRT lands $145 million to push radiopharma pipeline | Pharmaceutical | The Pharmaletter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE4ySTNvQU02SHJ6dVFnMHRzYnptQ1VpTjNvallwV3FCVm5jbEZ2WmoyNW1BUHc2ZE1Zc0Nxa3l3V3liRGp6cnpqRmFFWFhhdWJ4RTVJRmZpbER6UU4xY2FiUA?oc=5","date":"2025-06-04","type":"pipeline","source":"Market.us Media","summary":"Proton Therapy Market Growth, Trend Analysis | CAGR of 13.1% - Market.us Media","headline":"Proton Therapy Market Growth, Trend Analysis | CAGR of 13.1%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQSFpjaGdWTm5BNEhKWHQtOWVZYzdhZFpFQVQta1ljdWhXcnNGTmN1MjRkMWlYMFlHSENJZUNsMmFIZ0Z4TnlFV3Q3emk3OUhVbzhEVXpfZWhSMTZMRWV4VW1jLWRFVnNGdHZOVVcyYkpEYzFQa092Mm50dHRmNnVKVGVrTUpkZVNETHow?oc=5","date":"2025-04-18","type":"pipeline","source":"The Washington Post","summary":"China’s restrictions on rare earths could hurt U.S. health care - The Washington Post","headline":"China’s restrictions on rare earths could hurt U.S. health care","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTFBBdkNNeUNNeTFKbzJmUGN3S2h6MER1VmRxcU9VbmtLeUZnelBlbTFFMWFyRnF0el9tbl9zdXYtRTRUTW9BRm5nOXp2OXZuUGZLRmVreDlFZ3pmWVc3OTYwbEY5SHI?oc=5","date":"2025-02-21","type":"pipeline","source":"Market.us","summary":"Proton therapy Market Size, Growth Analysis | CAGR of 13.1% - Market.us","headline":"Proton therapy Market Size, Growth Analysis | CAGR of 13.1%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1WN3hBRmg1WUp2bWRhZHhXQ2Zyc19KRXAxLWxtak96Q1BkaVJtenh3clI2WkwyaURVQXBLQXFBYURLcHBIUVNVaTFTTm5OMl9sLXVSb1RtY3JzbS0wc3RZWENzUEVrdDlONEhZVHBUWmRMTGlSWnBFWFRQSEM?oc=5","date":"2024-05-01","type":"pipeline","source":"jnm.snmjournals.org","summary":"Landscape of Nuclear Medicine in China and Its Progress on Theranostics - jnm.snmjournals.org","headline":"Landscape of Nuclear Medicine in China and Its Progress on Theranostics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxPQ3FyUWR4UTBTQ3dMZHdNc3pwTUdidktOaTJuS21HaHkzRGtqSXlKZjE3SVRaOHhudzZQQ1lIRWRCSno1TU1WcmpEOUpHMUVJSExaTmItMzU0eVVUWDhld3JpUkZ6SHJXQXJhaGZzV2x5bUJfZmlsalYyMjkzXzZ6SDBkM1hhdEhuYVJEd2hPaWwwT1pKOWIzMHVfRXZYdGN4OVFMTlFIU1ppVm9YRmJMVkhTZjdZNk1zeHp5Z2NxMWxrWmJ4QUNmVDFMLThhWThpOHJnMHNOd0Y5X0ZqQ0laNkNJbi1vb2IzcUhYaWdkd3ZFNk9fMlNidQ?oc=5","date":"2019-07-16","type":"pipeline","source":"prnewswire.com","summary":"BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology - prnewswire.com","headline":"BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}